Novo Nordisk A/S Common Stock (NY:NVO)

Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly? ↗

November 20, 2025

Novo Nordisk just addressed a problem that has prevented some from taking these drugs.

European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗

November 19, 2025

Via MarketBeat

Down 45% Year-to-Date, Novo Nordisk Ignites a Price War ↗

November 19, 2025

Via MarketBeat

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

November 19, 2025

European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial...

Novo Nordisk is investing aggressively to improve its pipeline of drugs in development.

Should Investors Buy Novo Nordisk Stock Near Its Near 52-Week Low? ↗

November 19, 2025

Indianapolis, IN – November 19, 2025 – Eli Lilly and Company (NYSE: LLY), the pharmaceutical titan, finds itself at the epicenter of market speculation, firmly placed on "stock split watch" as its...

Eli Lilly on "Stock Split Watch": A Deep Dive into a Pharmaceutical Giant's Future

November 19, 2025

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line.

Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle? ↗

November 18, 2025

The market is hopping with interesting news.

Can AI Drive Peloton's Comeback? ↗

November 18, 2025

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients ↗

Topics Artificial Intelligence

November 18, 2025

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.

Via Benzinga

Oprah Winfrey-Backed Wellness Stock Stumbles As GLP-1 Boom Reshapes Consumer Habits: Growth Score Plummets ↗

November 18, 2025

Prominent weight-loss and wellness company, WW International Inc. (NASDAQ: WW), backed by renowned talk show host Oprah Winfrey, has seen better days, with the company filing for bankruptcy early this...

Via Benzinga

Topics Bankruptcy

Price Over Earnings Overview: Novo Nordisk ↗

November 17, 2025

Via Benzinga

Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗

November 17, 2025

With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.

Via Benzinga

Topics ETFs

Novo Nordisk Leans Into Affordability Amid Rising Competition ↗

November 17, 2025

Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.

Via Benzinga

Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control ↗

November 17, 2025

Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation.

Via Benzinga

Omeros (OMER) Q3 2025 Earnings Call Transcript ↗

November 17, 2025

Omeros (OMER) Q3 2025 Earnings Call Transcript

Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.

Topics Derivatives Earnings

How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration ↗

November 17, 2025

Via Investor's Business Daily

Topics Government

Novo Nordisk Offers WeGovy, Ozempic For $199 A Month As It Takes On Eli Lilly’s Zepbound ↗

November 17, 2025

The Danish drugmaker has announced that this offer is applicable to cash-paying patients looking to purchase introductory doses of Wegovy and Ozempic.

Healthcare stocks have far outperformed the broader market over the past month.

Topics Artificial Intelligence

This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000? ↗

November 17, 2025

Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? ↗

Topics ETFs Government World Trade

November 16, 2025

Investors will be watching what Trump makes happen.

Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market ↗

Topics Government

November 14, 2025

Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the sell side are WBD, Bill.com and TuneIn.

Via Benzinga

Novo Nordisk Brings Back Former CEO To Lead Board ↗

November 14, 2025

Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday.

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.

Topics Artificial Intelligence Economy Intellectual Property

Why Did Scholar Rock Soar 26% Today? ↗

November 14, 2025

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market.

Topics Earnings

Ozempic Maker Novo Nordisk Faces Board Shakeup ↗

November 14, 2025

Via Benzinga

Is It Too Late to Buy Novo Nordisk After the Drop? ↗

November 14, 2025

Analysts still see 52% upside for Novo Nordisk -- find out whether its blockbuster drugs can spark a major rebound in 2025.

There is hardly a dull moment for the drugmaker these days.

Why Is Everyone Talking About Novo Nordisk Stock? ↗

November 14, 2025

Novo Nordisk Stock Falls Premarket As Investors Brace For Contentious Vote To Reinstate Former CEO ↗

November 14, 2025

The board overhaul follows mass resignations triggered by internal disputes over Novo’s direction.

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗

November 13, 2025